The present disclosure relates to methods of using cisplatin active agents in which reduced organ toxicity is observed are provided. In the subject methods, an effective amount is administrated to the host before administration of an effective amount of cisplatin active agents. The cisplatin toxicity reducing agent comprising of stable bismuth(III) complexes or pharmaceutically acceptable salts reduces the levels of undesired toxicity of cisplatin active agents without compromising their anticancer activity. Also provided are methods for use in practicing the subject methods in the treatment of different disease conditions.

The present disclosure relates to methods of using cisplatin active agents in which reduced organ toxicity is observed are provided. In the subject methods, an effective amount is administrated to the host before administration of an effective amount of cisplatin active agents. The cisplatin toxicity reducing agent comprising of stable bismuth(III) complexes or pharmaceutically acceptable salts reduces the levels of undesired toxicity of cisplatin active agents without compromising their anticancer activity. Also provided are methods for use in practicing the subject methods in the treatment of different disease conditions.

The present disclosure relates to methods of using cisplatin active agents in which reduced organ toxicity is observed are provided. In the subject methods, an effective amount is administrated to the host before administration of an effective amount of cisplatin active agents. The cisplatin toxicity reducing agent comprising of stable bismuth(III) complexes or pharmaceutically acceptable salts reduces the levels of undesired toxicity of cisplatin active agents without compromising their anticancer activity. Also provided are methods for use in practicing the subject methods in the treatment of different disease conditions.

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating acute wounds, chronic wounds and/or a wound or epithelial tissue surface that contains bacterial biofilm, including unexpected synergy between bismuth-thiol (BT) compounds and certain antibiotics, to provide topical formulations including antiseptic formulations, for management and promotion of wound healing and in particular infected wounds. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating gram-negative bacterial infections.

α-Bi.sub.2O.sub.3 NPs exhibit not only potent broad-spectrum antibacterial activity of killing both Gram-negative (MIC=0.75 μg/mL vs. P. aeruginosa) and Gram-positive (MIC=2.5 μg/mL vs. S. aureus) bacteria, but they are also effective against Ag-resistant and carbapenem-resistant bacteria (MICs=1.0 μg/mL and 1.25 μg/mL, respectively), and they are able to sensitize bacteria towards meropenem (mero), acting synergistically and thus allowing for its continued use with smaller therapeutic doses (fractional inhibitory concentration=0.45). Importantly, unlike other technologies that have been considered as effective metal antimicrobials, α-Bi.sub.2O.sub.3 NPs do not contribute to the generation of antimicrobial resistant phenotypes with no resistance observed after 30 passages. The Bi-based materials represent a critical tool against multidrug resistant bacteria.

α-Bi.sub.2O.sub.3 NPs exhibit not only potent broad-spectrum antibacterial activity of killing both Gram-negative (MIC=0.75 μg/mL vs. P. aeruginosa) and Gram-positive (MIC=2.5 μg/mL vs. S. aureus) bacteria, but they are also effective against Ag-resistant and carbapenem-resistant bacteria (MICs=1.0 μg/mL and 1.25 μg/mL, respectively), and they are able to sensitize bacteria towards meropenem (mero), acting synergistically and thus allowing for its continued use with smaller therapeutic doses (fractional inhibitory concentration=0.45). Importantly, unlike other technologies that have been considered as effective metal antimicrobials, α-Bi.sub.2O.sub.3 NPs do not contribute to the generation of antimicrobial resistant phenotypes with no resistance observed after 30 passages. The Bi-based materials represent a critical tool against multidrug resistant bacteria.

Compositions and methods for treating a subject for a SARS-CoV-2 infection in a subject in need thereof are disclosed. The composition includes one or more Bismuth (III)-containing compounds, an analog thereof, or pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier, and are used alone or in combination with a thiol-containing small molecule compound. Exemplary Bismuth (III)-containing compounds include Colloidal Bismuth Subcitrate (CBS); ranitidine bismuth citrate (RBC); Bi (TPP) (TPP: tetraphenylporphyrinate); and Bi (TPyP) (TPyP: tetra (4-pyridyl) porphyrin). The disclosed compounds and compositions can be used to treat a SARS-CoV-2 infection in a subject in need thereof. The compositions can be administered to a subject presently suffering from an infection of the SARS-CoV-2, who is exhibiting one or more symptoms of COVID-19. The compositions can also be administered to a subject that has been exposed to the SARS-CoV-2 but is asymptomatic.

Compositions and methods for treating a subject for a SARS-CoV-2 infection in a subject in need thereof are disclosed. The composition includes one or more Bismuth (III)-containing compounds, an analog thereof, or pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier, and are used alone or in combination with a thiol-containing small molecule compound. Exemplary Bismuth (III)-containing compounds include Colloidal Bismuth Subcitrate (CBS); ranitidine bismuth citrate (RBC); Bi (TPP) (TPP: tetraphenylporphyrinate); and Bi (TPyP) (TPyP: tetra (4-pyridyl) porphyrin). The disclosed compounds and compositions can be used to treat a SARS-CoV-2 infection in a subject in need thereof. The compositions can be administered to a subject presently suffering from an infection of the SARS-CoV-2, who is exhibiting one or more symptoms of COVID-19. The compositions can also be administered to a subject that has been exposed to the SARS-CoV-2 but is asymptomatic.